Phenotypic profiles and functional genomics in Alzheimer's disease and in dementia with a vascular component

被引:24
作者
Cacabelos, R [1 ]
Fernández-Novoa, L
Corzo, L
Amado, L
Pichel, V
Lombardi, V
Kubota, Y
机构
[1] EuroEspes Biomed Res Ctr, Int CNS Diorders, EuroEspes Biotechnol, Bergondo 15166, Coruna, Spain
[2] Camilo Jose Cela Univ, Dept Biotechnol & Genom, Madrid, Spain
关键词
Alzheimer disease; vascular dementia; APOE; brain perfusion; brain atrophy; brain hemodynamics; structural genomics; functional genomics;
D O I
10.1179/016164104225017677
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Alzheimer's disease (AD) and dementia with vascular component (DVC) are the most prevalent forms of dementia. Both clinical entities share many similarities, but they differ in major phenotypic and genotypic profiles as revealed by structural and functional genomics studies. Comparative phenotypic studies have identified significant differences in 25% of more than 100 parametric variables, including anthropometry, cardiovascular function, aortic atherosclerosis, brain atrophy, blood pressure, blood biochemistry, hematology, thyroid function, folate and vitamin B, levels, brain hemodynamics and lymphocyte markers. The phenotypic profile of patients with DVC differs from that of AD patients in the following: anthropometric values (weight, height); cardiovascular function (ECG, heart rate); blood pressure; lipid metabolism (HDL-CHO, TGs); uric acid metabolism; peripheral calcium homeostasis; liver function (GOT, GPT, GGT); alkaline phosphatase; lactate dehydrogenase; red and white blood cells; regional brain atrophy (left temporal region, inter-hippocampal distance); and left anterior blood flow velocity. Functional genomics studies incorporating APOE-related changes in biological markers extended the difference between AD and DVC up to 57%. Brain perfusion studies show a severe brain hypoperfusion in dementia associated with enlarged age-dependent arterial perfusion times. Structural genomics studies with AD-related genes, including APP, MAPT, APOE, PSI, PS2, A2M, ACE, AGT, cFOS and PRNP genes, demonstrate different genetic profiles in AD and DVC, with an absolute genetic variation rate ranging from 30% to 80%, depending upon genes and genetic clusters. Single gene analysis identifies relative genetic variations ranging from 0% to 5%. The relative polymorphic variation in genetic clusters integrated by two, three or fourgenes associated with AD ranges from 1% to 3%. The main phenotypic differences between AD and DVC are genotype-dependent, especially in AD, probably indicating that different genomic factors are determinant for the expression of dementia symptoms which might be accelerated or induced by environmental and/or cerebrovascular factors.
引用
收藏
页码:459 / 480
页数:22
相关论文
共 82 条
[1]
Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Alzheimer disease [J].
Aliev, G ;
Smith, MA ;
Obrenovich, ME ;
De la Torre, JC ;
Perry, G .
NEUROTOXICITY RESEARCH, 2003, 5 (07) :491-504
[2]
Prostaglandins and other lipid mediators in Alzheimer's disease [J].
Bazan, NG ;
Colangelo, V ;
Lukiw, WJ .
PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2002, 68-9 :197-210
[3]
BJORKHEM I, 2004, IN PRESS ARTERIOSCLE
[4]
Co-localization of cholesterol, apolipoprotein E and fibrillar Aβ in amyloid plaques [J].
Burns, MP ;
Noble, WJ ;
Olm, V ;
Gaynor, K ;
Casey, E ;
LaFrancois, J ;
Wang, L ;
Duff', K .
MOLECULAR BRAIN RESEARCH, 2003, 110 (01) :119-125
[5]
Amyloid β-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists [J].
Butterfield, D. Allan ;
Griffin, Sue ;
Munch, Gerald ;
Pasinetti, Giulio Maria .
JOURNAL OF ALZHEIMERS DISEASE, 2002, 4 (03) :193-201
[6]
Butterfield DA, 2002, NEUROBIOL AGING, V23, P655
[7]
Amyloid β-peptide (1-42)-induced oxidative stress and neurotoxicity:: Implications for neurodegeneration in Alzheimer's disease brain.: A review [J].
Butterfield, DA .
FREE RADICAL RESEARCH, 2002, 36 (12) :1307-1313
[8]
Proteomics in Alzheimer's disease: insights into potential mechanisms of neurodegeneration [J].
Butterfield, DA ;
Boyd-Kimball, D ;
Castegna, A .
JOURNAL OF NEUROCHEMISTRY, 2003, 86 (06) :1313-1327
[9]
A functional Genomics approach to the analysis of biological markers in Alzheimer disease [J].
Cacabelos, R ;
Lombardi, P ;
Fernández-Novoa, L ;
Kubota, Y ;
Corzo, L ;
Pichel, V ;
Takeda, M .
MOLECULAR NEUROBIOLOGY OF ALZHEIMER DISEASE AND RELATED DISORDERS, 2004, :236-285
[10]
Pharmacogenomic studies with a combination therapy in Alzheimer's disease [J].
Cacabelos, R ;
Fernández-Novoa, L ;
Pichel, V ;
Lombardi, P ;
Kubota, Y ;
Takeda, M .
MOLECULAR NEUROBIOLOGY OF ALZHEIMER DISEASE AND RELATED DISORDERS, 2004, :94-107